Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1).

The Nasdaq Listing Qualifications Department confirmed on Dec 17, 2025 that, as of Dec 16, 2025, Sutro's common stock maintained an average closing price of at least $1.00 following the company's 1:10 reverse stock split that became effective on Dec 3, 2025. As a result, the company's shares are no longer considered below the minimum bid price requirement and the company has regained continued listing compliance.

Positive

• Regained Nasdaq compliance under Rule 5450(a)(1) as of Dec 16, 2025
• 1:10 reverse stock split effective Dec 3, 2025 produced required $1.00 average closing price

Negative

• Shares were previously below Nasdaq's minimum bid price requirement prior to the reverse split
• Completed 1:10 reverse stock split reduced outstanding share count per share consolidation

Key Figures

Minimum bid price $1.00 Nasdaq Rule 5450(a)(1) average closing share price threshold

Reverse stock split ratio 1-for-10 Reverse stock split effective December 3, 2025

Current share price $9.81 Price prior to compliance confirmation article

Price vs 52-week high -56.01% Distance from 52-week high of $22.30

Price vs 52-week low 87.54% Distance above 52-week low of $5.231

Market cap $84,597,563 Equity value prior to Nasdaq compliance news

20-day avg volume 110,804 shares Liquidity benchmark vs today’s volume

Today’s volume 99,119 shares Pre-news trading activity vs 20-day average

Market Reality Check

$9.13 Last Close

Volume Volume 99,119 is below the 20-day average of 110,804 (rel. volume 0.89x). normal

Technical Price $9.81 is trading above the 200-day MA at $8.79.

Peers on Argus

STRO was down 1.21% pre-news. Peers were mixed: several declined (e.g., IGMS -2.31%, XBIT -2.39%) while ENTX rose 1.46%, suggesting stock-specific factors rather than a unified sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 16	Inducement equity grants	Neutral	-1.2%	New-hire stock options and RSUs granted under equity inducement plan.
Dec 03	Clinical trial start	Positive	+19.2%	First cohort dosed in Phase 1 trial of STRO-004 ADC in solid tumors.
Dec 01	Reverse stock split	Negative	-12.8%	1-for-10 reverse split implemented to address Nasdaq $1.00 bid requirement.
Nov 12	R&D day update	Positive	-0.3%	Virtual R&D Day highlighting ADC pipeline, including STRO-004 and STRO-227 plans.
Nov 06	Q3 2025 earnings	Neutral	-4.3%	Q3 2025 results and cash runway update alongside ADC program progress.

Pattern Detected

Regulatory and corporate actions (reverse split, compliance, inducement grants) have often seen modest or negative price reactions, while clinical milestones like new trial dosing drew the strongest positive move.

Recent Company History

Over the last two months, Sutro Biopharma has combined corporate cleanup steps with pipeline progress. A 1-for-10 reverse split announced on Dec 1, 2025 aimed to restore Nasdaq bid price compliance but saw a -12.82% reaction. A Phase 1 dosing update for STRO‑004 on Dec 3, 2025 produced a strong +19.21% move. Subsequent R&D and inducement grant news drew limited or negative responses. Today’s announcement confirms the reverse split has achieved its compliance objective.

Market Pulse Summary

This announcement confirms Sutro has regained compliance with Nasdaq’s $1.00 minimum bid price requirement following its 1-for-10 reverse stock split effective December 3, 2025. That resolves a listing deadline flagged in prior filings and removes the immediate risk of delisting for bid-price reasons. Recent history shows that investors responded most strongly to clinical updates, while corporate actions gained more muted reactions, so future attention may focus on upcoming STRO-004 data and financing disclosures.

Key Terms

reverse stock split financial

"following the Company’s 1:10 reverse stock split that became effective"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

Nasdaq Stock Market financial

"it has regained compliance with the Nasdaq Stock Market (Nasdaq)"

The Nasdaq Stock Market is a place where many companies' shares are bought and sold, functioning like a marketplace for investing in businesses. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping people grow their wealth or fund business growth. Known for hosting many technology and innovative companies, it is a key indicator of the health of those sectors.

minimum bid price requirement regulatory

"below the minimum bid price requirement of Rule 5450(a)(1)"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

antibody drug conjugates (ADCs) medical

"pioneering site-specific and novel-format antibody drug conjugates (ADCs)"

Antibody drug conjugates (ADCs) are specialized medicines that combine a targeted antibody with a powerful drug, designed to attack specific disease cells while minimizing harm to healthy ones. This approach allows for more precise treatment, often leading to better outcomes. For investors, ADCs represent innovative therapies with the potential for significant market impact and growth in the healthcare sector.

clinical-stage medical

"a clinical-stage oncology company pioneering site-specific"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has regained compliance with the Nasdaq Stock Market (Nasdaq) continued listing standard for minimum share price under Rule 5450(a)(1) of the Nasdaq Listing Qualifications.

On December 17, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of December 16, 2025 the Company’s common stock has maintained an average closing share price of at least $1.00 following the Company’s 1:10 reverse stock split that became effective on December 3, 2025. The Company’s shares are no longer considered to be below the minimum bid price requirement of Rule 5450(a)(1), and as a result the Company has regained compliance with the Nasdaq continued listing standard.

About Sutro Biopharma

Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Sutro’s future stock price, the effects of the reverse stock split on stockholders, continued compliance with Nasdaq listing standards and Sutro’s ability to remain listed on the Nasdaq Global Market. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contact:
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

What did Sutro Biopharma (STRO) announce on Dec 17, 2025 about Nasdaq compliance?

Sutro announced it regained compliance with Nasdaq Rule 5450(a)(1) after maintaining an average closing price ≥ $1.00 as of Dec 16, 2025.

How did the 1:10 reverse stock split affect Sutro Biopharma (STRO)?

The 1:10 reverse stock split effective Dec 3, 2025 consolidated shares and helped the stock reach the required average closing price.

When did Sutro Biopharma's (STRO) reverse split become effective?

The company completed a 1:10 reverse stock split that became effective on Dec 3, 2025.

What date confirmed Sutro Biopharma (STRO) met Nasdaq's minimum bid price?

Nasdaq confirmed on Dec 17, 2025 that as of Dec 16, 2025 Sutro's average closing share price met the $1.00 requirement.

Does regaining compliance mean Sutro Biopharma (STRO) will avoid delisting?

Regaining compliance with Rule 5450(a)(1) removes the minimum bid price deficiency that could have led to delisting under that specific standard.